Hormonal
Obese gut microbiota reduces the capacity to metabolize ethanolamine, leading to its accumulation in the gut, which triggers a molecular cascade (ARID3a/miR-101a-3p/Zo1) that weakens intestinal barriers, causing leaky gut, systemic inflammation, and glucose metabolic dysfunction.
If you are obese or have type 2 diabetes, your gut microbiome may be failing to break down ethanolamine, leading to gut leakiness and inflammation. Supporting your gut with probiotics that specifically metabolize ethanolamine may help restore gut barrier function and improve metabolic health. Focus on dietary patterns that support a diverse microbiome.
We discovered that the reduced capacity of the microbiota from both obese mice and humans to metabolise ethanolamine results in ethanolamine accumulation in the gut, accounting for induction of intestinal permeability. Elevated ethanolamine increased the expression of microRNA-miR- 101a- 3p by enhancing ARID3a binding on the miR promoter. Increased miR- 101a- 3p decreased the stability of zona occludens- 1 (Zo1) mRNA, which in turn, weakened intestinal barriers and induced gut permeability, inflammation and abnormalities in glucose metabolism.
Why this rating
Strong mechanistic evidence in mice and human observational data, plus proof-of-concept with probiotic therapy, but lacks large-scale randomized controlled trials in humans for the specific probiotic.
Source
A mechanism by which gut microbiota elevates permeability and inflammation in obese/diabetic mice and human gut
Sidharth P. Mishra et al. · Gut · 2023
DOI 10.1136/gutjnl-2022-327365
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →